Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer-the Experience of a Tertiary Cancer Center

• Príomhchruthaitheoirí: Călin Căinap (Údar), Ovidiu-Vasile Bochiş (Údar), Cătălin Vlad (Údar), Raluca Popita (Údar), Patriciu Achimaş-Cadariu (Údar), Andrei Havasi (Údar), Andreea Vidrean (Údar), Alexandra Dranca (Údar), Andra Piciu (Údar), Anne-Marie Constantin (Údar), Tiberiu Tat (Údar), Maniu Dana (Údar), Ovidiu Crişan (Údar), Cosmin Vasile Cioban (Údar), Ovidiu Bălăcescu (Údar), Ovidiu Coza (Údar), Loredana Bălăcescu (Údar), Monica Mihaela Marta (Údar), Madalina Bota (Údar), Simona Căinap (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2021-03-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Background: Colorectal cancer (CRC) is the third most common cancer in Europe, with an annual increase in incidence ranging between 0.4 and 3.6% in various countries. Although the development of CRC was extensively studied, limited number of new therapies were developed in the last few years. Bevaci...